Literature DB >> 33465729

Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma.

Bo Chen1, Chuan Hu2, Liqing Jiang3, Zhouxia Xiang1, Ziyi Zuo1, Yangjun Lin1, Chuan Liu4.   

Abstract

BACKGROUND: Immune-related genes (IRGs) are associated with the prognosis of different cancers and are helpful for the diagnosis and management of systematic treatment for cancer patients. However, there have been a few corresponding studies in pancreatic adenocarcinoma (PAAD).
METHODS: The data of PAAD patients were obtained from the TCGA, GEO, and ICGC databases. Additionally, the expression profiles of the normal pancreas from the GTEx database were used to screen differentially expressed immune-related genes (DEIRGs). Cox regression analyses were used to explore overall survival (OS)- and progression-free survival (PFS)-related DEIRGs and to establish two nomograms for PAAD prognosis. Finally, transcription factor (TF), immune infiltration, and unsupervised consensus analyses were performed to understand the potential mechanisms.
RESULTS: An OS-prognostic signature based on seven DEIRGs and a PFS-prognostic signature based on seven DEIRGs were generated, and their robust prognostic ability was confirmed by ROC curves (OS: 0.736 ~ 0.774, PFS: 0.732 ~ 0.840). According to the risk score, the OS and PFS of the high-risk group were poorer than those of the low-risk group in the training set and four external validation sets. In addition, two nomograms based on the signatures and clinical variables also showed excellent discrimination. And two hub regulatory pathways were successfully validated in several independent datasets. Discernable patterns of DEIRGs in unsupervised consensus analysis showed that patients with low expression of immune checkpoints had a favorable prognosis.
CONCLUSION: Two DEIRG-based signatures can be used as independent tools for the prognostic prediction of PAAD and to provide potential novel immunotherapy targets.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Immune features; Immune-related genes; Nomogram; Pancreatic adenocarcinoma; Prognosis; Transcription factor

Mesh:

Substances:

Year:  2021        PMID: 33465729     DOI: 10.1016/j.intimp.2020.107359

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

1.  An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma.

Authors:  Zhijun Xiao; Jinyin Li; Qian Yu; Ting Zhou; Jingjing Duan; Zhen Yang; Cuicui Liu; Feng Xu
Journal:  Front Pharmacol       Date:  2021-12-23       Impact factor: 5.810

2.  Development of epithelial-mesenchymal transition-related lncRNA signature for predicting survival and immune microenvironment in pancreatic cancerwithexperiment validation.

Authors:  Yong Gao; Jinhui Liu; Baobao Cai; Qun Chen; Guangfu Wang; Zipeng Lu; Kuirong Jiang; Yi Miao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  Up-regulation of S100P predicts the poor long-term survival and construction of prognostic signature for survival and immunotherapy in patients with pancreatic cancer.

Authors:  Wenbo Zou; Lincheng Li; Zizheng Wang; Nan Jiang; Fei Wang; Minggen Hu; Rong Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  A Novel Immune-Related Prognostic Signature Predicting Survival in Patients with Pancreatic Adenocarcinoma.

Authors:  Xiao Zhang; Xiaomian Li; Jun Xie; Qian Zhu; Yufeng Yuan
Journal:  J Oncol       Date:  2022-03-18       Impact factor: 4.375

5.  An immune-related gene prognostic risk index for pancreatic adenocarcinoma.

Authors:  Yang Su; Ruoshan Qi; Lanying Li; Xu Wang; Sijin Li; Xuan Zhao; Rui Hou; Wen Ma; Dan Liu; Junnian Zheng; Ming Shi
Journal:  Front Immunol       Date:  2022-07-26       Impact factor: 8.786

6.  Identification of Survival-Associated Hub Genes in Pancreatic Adenocarcinoma Based on WGCNA.

Authors:  Liya Huang; Ting Ye; Jingjing Wang; Xiaojing Gu; Ruiting Ma; Lulu Sheng; Binwu Ma
Journal:  Front Genet       Date:  2022-01-03       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.